CLIMB BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
CLIMB BIO, INC. (CLYM) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.20% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-06
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.20%, a 2.44% increase year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.80%, a 17.39% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 3.90%, a 5.41% increase year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 4.10%, a 4.65% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.30%, a 7.50% increase from fiscal 2024.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.00%, a 8.40% increase from fiscal 2023.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.69%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.20% 10-Q · filed 2026-08-06 | 3.90% 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 3.80% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 4.30% 10-K · filed 2026-03-05 | |||
| 2025-09-30 | 3.90% 10-Q · filed 2025-11-06 | 4.40% 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | 4.10% 10-Q · filed 2026-08-06 | 4.40% 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | 4.60% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 4.00% 10-K · filed 2026-03-05 | |||
| 2024-09-30 | 3.70% 10-Q · filed 2025-11-06 | 4.00% 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 4.30% 10-Q · filed 2025-08-12 | 4.30% 10-Q · filed 2025-08-12 | ||
| 2023-12-31 | 3.69% 10-K · filed 2025-03-25 | |||
| 2023-09-30 | 3.69% 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 3.69% 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |